您好,欢迎访问中山大学肿瘤防治中心官方网站!
Research Data Deposit 内部网 职工邮箱 图书馆 OA系统 医生门户 English
院士风采 首席专家 临床专家 科研学者 人才名录 护理专家
首页
  • 文石军

    职务:中山大学“百人计划”引进人才
    职称:博士、研究员、博士生导师
    专长:抗肿瘤代谢和表观遗传药物合成及机制研究
    中山大学肿瘤防治中心,研究员,博士生导师
    研究方向:抗肿瘤代谢和表观遗传药物合成及机制研究
    地址:中山大学肿瘤防治中心2号楼708室
    E-mail: wenshj@sysucc.org.cn
    电话:020-87342283,020-39943091

      中山大学“百人计划”入选者,分子医学/肿瘤学和药物化学博士生导师,从事抗肿瘤代谢和表观遗传药物合成及机制研究。吉林大学化学系本科毕业,中国科学院上海有机化学研究所博士毕业。2005年至2010年曾在英国南安普顿大学和剑桥大学进行博士后研究。目前,主持多项国家级和省部级项目。在Leukemia, Mol Cancer, Cancer Lett, Future Med Chem, Eur J Med Chem, J Med Chem, Angew Chem Int Ed, Adv Synth Catal, Organic Letters, Chem Eur J等杂志上发表高水平论文50多篇。近年来,发表第一和通讯作者高水平论文近30篇,其中IF>5的高水平论文有12篇,两项研究工作(Chem Eur J 2015,Org Lett 2014) 被国际引文杂志SYNFACTS专门评论。申请发明专利11项,其中获得授权3项、国际PCT专利1项。

    工作经历:
    1. 2017/12-至今:研究员,博士生导师,中山大学肿瘤防治中心,从事抗肿瘤代谢和表观遗传药物合成及机制研究
    2. 2010/10–2017/12:副研究员,中山大学“百人计划”入选者,中山大学肿瘤防治中心
    3. 2008/02–2010/05: 博士后,英国剑桥大学化学系和生物化学系,从事结核菌泛酸合成酶抑制剂研究
    4. 2005/06–2008/01: 博士后,英国南安普敦大学医学院和化学系,从事组蛋白去乙酰酶抑制剂研究 

    中山大学肿瘤防治中心,研究员,博士生导师

    研究方向:抗肿瘤代谢和表观遗传药物合成及机制研究
    地址:中山大学肿瘤防治中心2号楼708室
    E-mail: wenshj@sysucc.org.cn
    电话:020-87342283,020-39943091


      中山大学“百人计划”入选者,分子医学/肿瘤学和药物化学博士生导师,从事抗肿瘤代谢和表观遗传药物合成及机制研究。吉林大学化学系本科毕业,中国科学院上海有机化学研究所博士毕业。2005年至2010年曾在英国南安普顿大学和剑桥大学进行博士后研究。目前,主持多项国家级和省部级项目。在Leukemia, Mol Cancer, Cancer Lett, Future Med Chem, Eur J Med Chem, J Med Chem, Angew Chem Int Ed, Adv Synth Catal, Organic Letters, Chem Eur J等杂志上发表高水平论文50多篇。近年来,发表第一和通讯作者高水平论文近30篇,其中IF>5的高水平论文有12篇,两项研究工作(Chem Eur J 2015Org Lett 2014) 被国际引文杂志SYNFACTS专门评论。申请发明专利11项,其中获得授权3项、国际PCT专利1项。


    工作经历:

    1.   2017/12-至今:研究员,博士生导师,中山大学肿瘤防治中心,从事抗肿瘤代谢和表观遗传药物合成及机制研究

    2.   2010/10–2017/12:副研究员,中山大学“百人计划”入选者,中山大学肿瘤防治中心

    3.   2008/02–2010/05: 博士后,英国剑桥大学化学系和生物化学系,从事结核菌泛酸合成酶抑制剂研究

    4.   2005/06–2008/01: 博士后,英国南安普敦大学医学院和化学系,从事组蛋白去乙酰酶抑制剂研究


    主持/参与科研项目情况:

    1.   国家自然科学基金面上项目,81872440,“合成EZH2/LSD1双靶点抑制剂作为干预表观遗传的抗肿瘤新策略”,58万,2019/01-2022/12,主持

    2.   国家自然科学基金面上项目,81672952,“糖酵解新型抑制剂的合成优化及其对肺癌肿瘤干细胞杀灭作用的研究”,59万,2017/01–2020/12,主持。

    3.   广州市对外科技合作计划项目,201807010041,基于NOX酶新型抑制剂DQ285作为抗癌候选药物的研究,100万,2018-2021,主持 。

    4.   国家自然科学基金重点项目,81430060,肿瘤细胞氧化还原代谢异常的机制研究和干预策略,320万,2015/01-2019/12,主要参与。

    5.   广东省科技发展专项,2017A020215198,IDH1突变体R132H特异性抑制剂及其对脑胶质瘤治疗作用的研究,10万,2017/01-2019/12,主持。

    6.   广东省自然科学基金面上项目,2014A030313196,糖酵解抑制剂3-溴丙酮酸的构效关系及其抗肿瘤活性研究 ,10万,2015/01-2018/01,主持。

    7.   广东省科技计划对外合作项目,2013B051000034,抗癌新靶点NOX 酶高效抑制剂二苯并碘鎓盐的研发,25万,2014/08-2017/07,主持。

    8.   教育部博士点新教师项目,20110171120098,己糖激酶II 抑制剂作为抗肿瘤药物的设计与合成研究,4万,2011/01-2014/12,主持。

    9.   中山大学“百人计划”,以癌细胞糖酵解途径为靶标的抗肿瘤药物研究及其构建生物活性分子骨架的有机合成方法学研究,30万,2010/11-2012/10,主持。

    10.  广州市科技计划科学研究专项(重点项目),201504010038,基于肿瘤代谢异常的抗癌新药研究,300万,2015/03-2018/03,参与。

    11.  广州市科技计划健康医疗协同创新重大专项,201508020250,基于肿瘤代谢异常关键靶点的抗癌新药MET-709及其相应的临床分子标志物的研发,450万,2014/11-2017/12,参与。


    发表的高水平论文(#共同第一作者,*通讯作者):

    2018

    2.Guo-Xin Hou, Pan-pan Liu, Mengqi Yang, Jianwei Liao, Jing Yang, Yumin Hu, Wen-Qi Jiang, Shijun Wen,* Peng Huang* Elimination of stem-like cancer cell side-population by auranofin through modulation of ROS and glycolysis Cell Death Disease, 2018 Jan 24;9(2):89. (IF 5.638)

    4.Shijun Wen,* Jiankang Wang, Panpan Liu, Yiqing Li, Wenhua Lu, Yumin Hu, Jinyun Liu, Zhiyuan He, Peng Huang.* Novel combination of histone methylation modulators with therapeutic synergy against acute myeloid leukemia in vitro and in vivo Cancer Lett. 2018 Jan 28; 413: 35-45. (IF 6.491)

    5.Tang Gao,Xiaozheng Cao, Anyao Bi,Jie Dong,Shuai Huang,Xueyan Huang,Shijun Wen,Wenbin Zeng. An Aza-Cope mediated fluorescent probe based on aggregation-induced emission for highly selective and sensitive detection of formaldehyde in living cells and tissues, Sensors and Actuators B: Chemical, 2018 Nov; 273: 1139-1145. (IF 5.667)

    6.Zhang T, Zhao M, Lu D, Wang S, Yu F, Guo L, Wen S, Wu B, REV-ERBa Regulates CYP7A1 through Repression of Liver Receptor Homolog-1, Drug Metab Dispos. 2018 Mar; 46(3): 248-258. ( IF 3.640)

    7.Li Y, Shi Q, Shao J, Yuan Y, Yang Z, Chen S, Zhou X, Wen S, Jiang ZX. Synthesis and biological evaluation of 20-epi-amino-20-deoxysalinomycin derivatives. Eur J Med Chem. 2018 Mar 25; 148: 279-290.(IF 4.816


    2017

    9.Jiankang Wang, Bingling Luo, Xiaobing Li, Jing Yang, Wenhua Lu, Yumin Hu, Peng Huang*, Shijun Wen*, Inhibition of cancer growth in vitro and in vivo by a novel ROS-modulating agent with ability to eliminate stem-like cancer cells. Cell Death Disease, 2017, 8(6):e2887. (IF 5.638)

    10.Xiaopeng Peng, Hongwen Luo, Fuhai Wu, Daqian Zhu, A. Ganesan, Peng Huang, Shijun Wen*, Synthesis of Fluorenes with an All-Carbon Quaternary Center via Palladium- Catalyzed Dual Arylation using Cyclic Diaryliodonium Triflates. Adv Synth Catal, 2017, 359, 1152-1156. (IF 5.123)

    11.Bingling Luo, Jiankang Wang, Xiaobing Li, Jing Yang, Wenhua Lu, Yumin Hu, Peng Huang, Shijun Wen*, New Mild and Simple Approach to Isothiocyanates: A Class of Potent Anticancer Agents. Molecules, 2017, 22(6). pii: E773. (IF 3.098)

    12.GX Hou, P Liu, J Yang, S Wen*, Mining expression and prognosis of topoisomerase isoforms in non-small-cell lung cancer by using Oncomine and Kaplan-Meier plotter. PLoS One, 2017, 12(3): e0174515. (IF 2.766)

    13.Qingbin Cui#, Shijun Wen#, Peng Huang*, Targeting cancer cell mitochondria as a therapeutic approach: recent updates, Future Med Chem, 2017, 9(9):929-949. (IF 3.969)

    14.H-Q Ju, G Zhan, A Huang, Y Sun, S Wen, J Yang, W-h Lu, R-h Xu, J Li, Y Li, G Garcia-Manero, P Huang*, Y Hu* ITD mutation in FLT3 tyrosine kinase promotes Warburg effect and renders therapeutic sensitivity to glycolytic inhibition, Leukemia, 2017 Oct;31(10):2143-2150 . (IF 10.023)

    15.Jianwei Liao, Pan-Pan Liu, Guoxin Hou, Jiajia Shao, Jing Yang, Kaiyan Liu, Wenhua Lu, Shijun Wen, Yumin Hu, Peng Huang*, Regulation of stem-like cancer cells by glutamine through beta-catenin pathway mediated by redox signaling, Molecular Cancer, 2017, 16(1): 51 DOI 10.1186/s12943-017-0623-x. (IF 7.776)

    16.Mengqi Yang, Panpan Liu, Kefeng Wang, Christophe Glorieux, Yumin Hu, Shijun Wen, Wenqi Jiang*, Peng Huang*, Chemotherapy induces tumor immune evasion by upregulation of programmed cell death ligand 1 expression in bone marrow stromal cells, Molecular Oncology, 2017, 11(4):358-372. (IF 5.264)

    17.Kaiyan Liu, Zhenjie Tang, Amin Huang, Ping Chen, Panpan Liu, Jing Yang,  Wenhua Lu, Jianwe Liao, Yicheng Sun, Shijun Wen, Yumin Hu,* Peng Huang*, Glyceraldehyde-3- phosphate dehydrogenase promotes cancer growth and metastasis through upregulation of SNAIL expression, Int J Oncol, 2017, 50 (1): 252-262. (IF 3.333)


    2016

    19.Ya-lin Tu Y-L, Chen Q-H, Wang S-N, Uri A, Yang X-H, Chu J-Q, Chen J-K, Luo B-L, Chen X-H, Wen S-J*, Pi R-B*. Discovery of lipoic acid-4-phenyl-1H-pyrazole hybrids as novel bifunctional ROCK inhibitors with antioxidant activity. RSC Adv, 2016, 6, 58516–58520. (IF 3.108)

    21.Amin Huang, Huai-Qiang Ju, Kaiyan Liu, Guilian Zhan, Daolu Liu, Shijun Wen, Guillermo Garcia-Manero, Peng Huang*, Yumin Hu*, Metabolic alterations and drug sensitivity of tyrosine kinase inhibitor resistant leukemia cells with a FLT3/ITD mutation, Cancer Letters, 2016, 377 (2): 149-157. (IF 6.491)

    22.Hung AW, Silvestre HL, Wen S, George GP, Boland J, Blundell TL, Ciulli A, Abell C. Optimization of Inhibitors of Mycobacterium tuberculosis Pantothenate Synthetase Based on Group Efficiency Analysis. ChemMedChem, 2016, 11, 38-42. (IF 3.009)

    23.Chen M, Liu Q, Tan M, Wen S, Pi R,  Lin D. Synthesis and biological evaluation of n-butylphthalide derivatives as anti-platelet aggregation agents, Natural Product Research, 2016, online, DOI:10.1080/14786419.2015.1136907. (IF 1.928)


    2015

    29.Chen M, Tan M, Jing M, Liu A, Liu Q, Wen S, Chen Z, Chao X, He X, Ramassamy C, Gao Y, Pi R, Berberine protects homocysteic acid-induced HT-22 cell death: involvement of Akt pathway. Metab Brain Dis, 2015, 30, 137-142. (IF 2.441)


    2014

    34.Chen M, Liu Q, Liu A, Tan M, Xie Z, Uri A, Chen Z, Huang G, Sun Y, Ge H, Liu P, Li M, Li X, Wen S*, P R*, Simply combining fasudil and lipoic acid in a novel multitargeted chemical entity potentially useful in central nervous system disorders. RSC Adv, 2014, 4, 37266-37269. (IF 3.108)

    35.Mageed, S.N.; Cunningham, F.; Hung, A.W.; Silvestre, H.L.; Wen, S.; Blundell, T.L.; Abell, C.; McConkey, G.A. Pantothenic acid biosynthesis in the parasite Toxoplasma gondii: a target for chemotherapy. Antimicrob Agents Chemother, 2014, 58, 6345-6353.(IF 4.225

    36.Wang, L.; Wang, R.; Jin, M.; Huang, Y.; Liu, A.; Qin, J.; Chen, M.; Wen, S.; Pi, R.; Shen, W. Carvedilol Attenuates 6-Hydroxydopamine-Induced Cell Death in PC12 Cells: Involvement of Akt and Nrf2/ARE Pathways. Neurochem Res, 2014, 39, 1733-1740.(IF 2.772


    2013

    39.Guan R, Xu X, Chen M, Hu H, Ge H,  Wen S*, Zhou S*, Pi R*, Advances in the studies of roles of Rho/Rho-kinase in diseases and the development of its inhibitors. Eur J Med Chem, 2013, 70, 613-622.(IF 4.816

    41.Zhou, B.; Zuo, Y.; Li, B.; Wang, H.; Liu, H.; Wang, X.; Qiu, X.; Hu, Y.; Wen, S.; Du, J.; Bu, X. Deubiquitinase Inhibition of 19S Regulatory Particles by 4-Arylidene Curcumin Analogue AC17 Causes NF-κB Inhibition and p53 Reactivation in Human Lung Cancer Cells. Mol Cancer Ther, 2013, 12, 1381-92.(IF 5.365

    42.Li, X.; Lu, W.; Hu, Y. Wen, S. Qian, C.; Wu, W.; Huang, P. Effective inhibition of nasopharyngeal carcinoma in vitro and in vivo by targeting glycolysis with oxamate. Int J Oncol, 2013, 43, 1710-1718.(IF 3.333


    2012年前

    43.Abrahams, G.L.; Kumar, A.; Savvi, S.; Hung, A.W.; Wen, S.; Abell, C.; Barry, C.E. 3rd; Sherman, D.R.; Boshoff, H.I.; Mizrahi, V. Pathway-Selective Sensitization of Mycobacterium tuberculosis for Target-Based Whole-Cell Screening. Chem. Biol. 2012, 19, 844-854.(IF 6.743

    44.Tiffon C., Adams J., van der Fits L., Wen S, Townsend P., Ganesan A., Hodges E., Vermeer M., Packham G. The histone deacetylase inhibitors Vorinostat and Istodax downmodulate IL10 expression in cutaneous T-cell lymphoma cells British Journal of Pharmacology 2011, 162,1590-1602.(IF 5.810

    45.Hung A.W., Silvestre H.L., Wen S, Ciulli A., Blundell T.L., Abell C. Application of fragment growing and fragment linking to the discovery of novel inhibitors of Mycobacterium tuberculosis pantothenate synthetase. Angew. Chem. Int. Ed. 2009, 48, 8452-8456.(IF 12.102

    46.Heikkila T.J., Surade S., Silvestre H.L., Dias M.V.B., Ciulli A., Bromfield K., Scott D., Howard N., Wen S., Wei A.H., Osborne D., Abell C. Blundell T.L. Fragment-based drug discovery in academia: experiences from a tuberculosis programme NATO Security through Science Series C: Environmental Security, 2009, 21-36.

    47.Wen S, Packham, G., Ganesan, A. Macrolactamization versus Macrolactonization: Total Synthesis of FK228, the Depsipeptide Histone Deacetylase Inhibitor J Org Chem, 2008, 73, 9353-9361. (IF 4.805

    48.Wen S, Carey K., Nakao Y., Fusetani N., Packham G., Ganesan A. Total Synthesis of Azumamide A and Azumamide E, Evaluation as Histone Deactylase Inhibitors, and Design of a More Potent Analogue Organic Letters 2007, 9 (6), 1105-1108. (IF 6.492)

    49.Yurek-George A., Cecil A., Mo A.H.K., Wen S, Rogers H., Maeda S., Yoshida M., Packham G., Ganesan A., The First Biologically Active Synthetic Analogues of FK228, the Depsipeptide Histone Deacetylase Inhibitor, J. Med. Chem. 2007; 50(23); 5720-5726.(IF 6.253

    50.Wen, SJ, Hu, T.-S., Yao, Z.-J. Macrocylization Studies and Total Synthesis of Cyclomarin C, an Anti-inflammatory Marine Cyclopeptide, Tetrahedron 2005, 61 (21), 4931-4938.(IF 2.377

    51.Wen, SJ, Yao, Z.-J. Total Synthesis of Cyclomarin C. Organic Letters 2004, 6 (16) 2721-2724. (IF 6.492)

    52.Wen, SJ, Zhang HY, Yao Z.-J. Synthesis of a fully protected (2S,3R)-N-(1 ',1 '-dimethyl-2 '-propenyl)-3-hydroxytryptophan from tryptophan. Tetrahedron Lett. 2002, 43, 5291-5294.(IF 2.125


    专利:

    3. 皮荣标,何细新,杨晓红,姜伊鸣,陈紫薇,陈美惠,王胜男,文石军,刘培庆,咖啡酸和阿魏酸的同二聚体,其制备方法及其药物组合物,ZL201410325895.6,2014.07.03,(已授权)。

    9. 皮荣标,涂亚林,文石军,王胜男,杨晓红,陈秋荷,陈景考,治疗中枢神经系统退行性疾病或脑肿瘤的化合物及其应用,专利申请号201610667749.0,2016.08.15。

    10. 皮荣标,涂亚林,文石军,王胜男,杨晓红,陈秋荷,陈景考,治疗中枢神经系统退行性疾病的化合物及其应用,专利申请号201610304191.X,2016.05.10。

    11. 皮荣标,陈美惠,文石军,刘奇,周世友,刘安民,刘培庆,法舒地尔-硫辛酸二联体的合成及其应用,专利申请号201410152907.X,2014.04.10。

     



    更新日期:2018年8月21日

     

访客通道
员工通道
关注肿瘤医院
留言建议 ×